Narrow search
Showing 1 - 10 of 38,205
Cover Image
Estimating the cost of strategic entry delay in pharmaceuticals : the case of Ambien CR
Shapiro, Bradley T. - In: Quantitative marketing and economics : QME 14 (2016) 3, pp. 201-231
Persistent link: https://www.econbiz.de/10011606135
Cover Image
Unpacking the effects of adverse regulatory events : Evidence from pharmaceutical relabeling
Higgins, Matthew J.; Yan, Xin; Chatterjee, Chirantan - In: Research policy : policy, management and economic … 50 (2021) 1, pp. 1-15
Persistent link: https://www.econbiz.de/10012663313
Cover Image
The diffusion of generics after patent expiry in Germany
Blankart, Katharina; Stargardt, Tom - In: The European journal of health economics : HEPAC ; … 17 (2016) 8, pp. 1027-1040
Persistent link: https://www.econbiz.de/10011660160
Cover Image
Chapter Twelve. Markets for Pharmaceutical Products
Scott Morton, Fiona; Kyle, Margaret - In: Handbook of health economics : volume 2, (pp. 763-823). 2011
This chapter describes the market for pharmaceuticals, which exceeded $500 million in sales in 2010. The industry is … also characterized by extensive regulation of almost every activity, from product development through manufacturing and … research and incentives for innovation. We then summarize the pricing and marketing of drugs in the US and several other …
Persistent link: https://www.econbiz.de/10014025576
Cover Image
Chapter 12. Pharmaceutical Innovation
Scherer, F.M. - 2010
pharmaceuticals. The changing methods by which drugs are discovered, the links between companies and academic science, the changing … character of public regulation, and the sharp rise in the cost per new approved drug are analyzed. Determining which new drugs …
Persistent link: https://www.econbiz.de/10014025164
Cover Image
R&D and market size : who benefits from orphan drug legislation?
Gamba, Simona; Magazzini, Laura; Pertile, Paolo - In: Journal of health economics 80 (2021), pp. 1-22
Persistent link: https://www.econbiz.de/10013179155
Cover Image
The tools of globalization : ways of regulating and the structure of the international regime for pharmaceuticals
Demortain, David - In: Review of international political economy : RIPE 22 (2015) 6, pp. 1249-1275
Persistent link: https://www.econbiz.de/10011453911
Cover Image
The economic driven by politics as values : the example of pharmaceuticals in France
Smith, Andy - In: New political economy 22 (2017) 6, pp. 611-627
Persistent link: https://www.econbiz.de/10011742973
Cover Image
Should product-specific advertisement be regulated in pharmaceutical markets?
Ishida, Junichiro; Takahara, Tsuyoshi - In: Journal of public economic theory 26 (2024) 2, pp. 1-37
Persistent link: https://www.econbiz.de/10014507649
Cover Image
The adoption of new prescription drugs is strongly associated with prior category prescribing rate
Stern, Philip; Wright, Malcom - In: International journal of research in marketing : IJRM ; … 33 (2016) 1, pp. 220-224
Persistent link: https://www.econbiz.de/10011490911